Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial

Reuters

2025/12/02

Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer's Antibody in Phase 2 Trial

Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug (ACU193), to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594769-en) on December 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588534700"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588534700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588534700?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588534700","market":"fut","top_or_hot":-1,"title":"Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer's Antibody in Phase 2 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug (ACU193), to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594769-en) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-02 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer's Antibody in Phase 2 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug (ACU193), to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594769-en) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL9y0Z90:1","article_id":"2588534700","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588534700","pubTimestamp":1764680442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease  conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug , to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.Disclaimer: This news brief was created by Public Technol","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","ABOS":"Acumen Pharmaceuticals, Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4539":"次新股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股"},"translate_title":"Acumen Pharmaceuticals在2期试验中推出用于阿尔茨海默病抗体的增强型大脑输送技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ABOS":0.9},"content_text":"Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer's Antibody in Phase 2 Trial\n    \n\n        Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug (ACU193), to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer's disease studies. The results were presented at the conference, and data posters are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594769-en) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}